Alphatec (NASDAQ:ATEC) Hits New 52-Week Low After Earnings Miss

Key Points

• New 52‑week low / earnings miss: Shares plunged to as low as $6.85 after Alphatec reported Q1 EPS of ($0.22) versus a consensus of ($0.01), triggering heavy-volume selling and reported institutional disposals (roughly $18M disclosed).
• Mixed operating results vs. long‑term targets: Revenue rose 13.6% YoY to $192.11M but missed the $197.51M estimate, while management reaffirmed an ambitious FY‑2026 outlook of about $882M revenue and $134M adjusted EBITDA—execution will determine whether that thesis holds.
• Liquidity boost but tempered sentiment: The company established a new senior secured syndicated credit facility to reduce financing risk, yet substantial insider sales (689,614 shares, ~$8.63M over 90 days) and analyst price‑target cuts have left market sentiment mixed despite a consensus "Moderate Buy" $20.64 target.

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) reached a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $6.85 and last traded at $7.0710, with a volume of 2676831 shares. The stock had previously closed at $10.23.

The medical technology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.21). The company had revenue of $192.11 million during the quarter, compared to analysts' expectations of $197.51 million. During the same period last year, the firm posted ($0.35) EPS. The firm's revenue for the quarter was up 13.6% compared to the same quarter last year.

Key Headlines Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Company re‑affirmed an ambitious FY‑2026 outlook — management is forecasting roughly $882M in 2026 revenue and $134M in adjusted EBITDA, which supports a longer‑term growth thesis if execution continues. MSN: Forecasts
• Positive Sentiment: Alphatec reported robust gross margins (GAAP ~71%, non‑GAAP ~72%) and year‑over‑year revenue growth (~13.6%), and provided investor materials and a slide deck highlighting operating improvements — these metrics help justify valuation if revenue momentum persists. BusinessWire: Q1 Results
• Positive Sentiment: Liquidity strengthened: Alphatec established a new senior secured syndicated credit facility, which reduces near‑term financing risk and supports growth investments. TipRanks: Credit Facility
• Neutral Sentiment: Earnings call transcript and investor presentation are available for detailed read‑throughs of product adoption, reimbursement commentary and margin drivers — useful for due diligence but not new headline news. Seeking Alpha: Call Transcript
• Negative Sentiment: Institutional selling: a fund disclosed ~$$18M of Alphatec sales last quarter and the stock plunged after the earnings release — large redemptions or reallocations can pressure the stock near term. Fool: Fund Selling
• Negative Sentiment: Mixed / missed results: reported Q1 EPS and revenue came in below some consensus figures (EPS hurt by reported miss vs. consensus), which triggered the immediate selloff and highlights execution risk against street expectations. MarketBeat: Earnings Recap
• Negative Sentiment: Analyst target reduced: Needham cut its price target from $25 to $14 (while keeping a buy rating), trimming upside assumptions and signaling more conservative near‑term expectations from some sell‑side firms. Benzinga: PT Cut

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ATEC shares. Barclays set a $24.00 target price on Alphatec in a report on Wednesday. Lake Street Capital reissued a "buy" rating on shares of Alphatec in a report on Wednesday. Canaccord Genuity Group set a $23.00 price target on Alphatec in a research report on Wednesday. Wells Fargo & Company upgraded Alphatec to a "strong-buy" rating in a research report on Wednesday, March 18th. Finally, Piper Sandler restated an "overweight" rating and set a $14.00 price target on shares of Alphatec in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $20.64.

Insider Transactions at Alphatec

In other Alphatec news, EVP David Sponsel sold 163,452 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $12.52, for a total value of $2,046,419.04. Following the transaction, the executive vice president directly owned 504,932 shares in the company, valued at approximately $6,321,748.64. This trade represents a 24.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Tyson Eliot Marshall sold 88,835 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $12.49, for a total value of $1,109,549.15. Following the completion of the transaction, the general counsel owned 559,459 shares in the company, valued at $6,987,642.91. The trade was a 13.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 689,614 shares of company stock valued at $8,634,850 over the last 90 days. 22.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ATEC. Summit Securities Group LLC bought a new position in shares of Alphatec in the 1st quarter worth $29,000. Aster Capital Management DIFC Ltd bought a new position in shares of Alphatec in the 3rd quarter worth $34,000. Osterweis Capital Management Inc. bought a new position in shares of Alphatec in the 2nd quarter worth $37,000. Northwestern Mutual Wealth Management Co. boosted its position in shares of Alphatec by 157.1% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company's stock worth $54,000 after purchasing an additional 1,571 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Alphatec in the 3rd quarter worth $73,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec Price Performance

The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.28 and a current ratio of 2.06. The firm has a market capitalization of $1.09 billion, a P/E ratio of -7.53 and a beta of 0.96. The company has a 50-day moving average price of $11.73 and a 200-day moving average price of $15.95.

Alphatec Company Profile

Alphatec Holdings, Inc NASDAQ: ATEC is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.